Ultime notizie per MAIA Biotechnology (AMEX:MAIA) Azioni

MAIA Biotechnology

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

MAIA Biotechnology Inc

<p>Goldman Sachs  analyst Manish Adukia   downgrades Infosys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFY#NYSE">INFY</a>) from Buy to Neutral.</p>


News

Downgrades

Analyst Ratings

INFY

Goldman Sachs Downgrades Infosys to Neutral

<p>DA Davidson  analyst Gary Tenner   maintains Triumph Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFIN#NASDAQ">TFIN</a>) with a Neutral and lowers the price target from $68 to $56.</p>


Price Target

TFIN

DA Davidson Maintains Neutral on Triumph Financial, Lowers Price Target to $56

<p>Guggenheim  analyst John Difucci   upgrades Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) from Sell to Neutral.</p>


Upgrades

Guggenheim Upgrades Salesforce to Neutral

<p>Dime Community Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCOM#NASDAQ">DCOM</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-22. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Dime Community Bancshares to report an <strong>earnings per share</strong> (EPS) of $0.58.</p>
<p>Dime Community Bancshares bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings Track Record</h3>
<p>The company's EPS missed by $0.03 in the last quarter, leading to a 0.61% drop in the share price on the following day.</p>
<p>Here's a look at Dime Community Bancshares's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.45</td>
<td>0.41</td>
<td>0.38</td>
<td>0.37</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.42</td>
<td>0.29</td>
<td>0.37</td>
<td>0.38</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>3.0%</td>
<td>-3.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745258541_0.png" alt="eps graph" /></p>
<h3>Market Performance of Dime Community Bancshares's Stock</h3>
<p>Shares of Dime Community Bancshares were trading at $25.21 as of April 18. Over the last 52-week period, shares are up 28.08%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/DCOM/earnings"><strong>To track all earnings releases for Dime Community Bancshares visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

DCOM

A Preview Of Dime Community Bancshares's Earnings

<p>QCR Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCRH#NASDAQ">QCRH</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-04-22. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that QCR Hldgs will report an <strong>earnings per share</strong> (EPS) of $1.51.</p>
<p>Investors in QCR Hldgs are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings Track Record</h3>
<p>In the previous earnings release, the company beat EPS by $0.17, leading to a 1.99% drop in the share price the following trading session.</p>
<p>Here's a look at QCR Hldgs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.76</td>
<td>1.52</td>
<td>1.40</td>
<td>1.30</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.93</td>
<td>1.78</td>
<td>1.73</td>
<td>1.59</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>0.0%</td>
<td>7.000000000000001%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745258531_0.png" alt="eps graph" /></p>
<h3>Market Performance of QCR Hldgs's Stock</h3>
<p>Shares of QCR Hldgs were trading at $66.93 as of April 18. Over the last 52-week period, shares are up 12.17%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/QCRH/earnings"><strong>To track all earnings releases for QCR Hldgs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


QCRH

What to Expect from QCR Hldgs's Earnings

<p>Hanmi Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAFC#NASDAQ">HAFC</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-04-22. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Hanmi Financial will report an <strong>earnings per share</strong> (EPS) of $0.57.</p>
<p>Anticipation surrounds Hanmi Financial's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS beat by $0.05, leading to a 7.21% increase in the share price on the subsequent day.</p>
<p>Here's a look at Hanmi Financial's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.53</td>
<td>0.48</td>
<td>0.47</td>
<td>0.52</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.58</td>
<td>0.49</td>
<td>0.48</td>
<td>0.50</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>7.000000000000001%</td>
<td>7.000000000000001%</td>
<td>-6.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745258523_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Hanmi Financial were trading at $21.49 as of April 18. Over the last 52-week period, shares are up 36.35%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/HAFC/earnings"><strong>To track all earnings releases for Hanmi Financial visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


HAFC

A Preview Of Hanmi Financial's Earnings

<p>DA Davidson  analyst Peter Winter   maintains Texas Capital Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>) with a Neutral and lowers the price target from $81 to $76.</p>


TCBI

DA Davidson Maintains Neutral on Texas Capital Bancshares, Lowers Price Target to $76

<p>Monarch Casino &amp; Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-04-22. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Monarch Casino &amp; Resort will report an <strong>earnings per share</strong> (EPS) of $1.03.</p>
<p>Monarch Casino &amp; Resort bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.24, which was followed by a 7.88% increase in the share price the next day.</p>
<p>Here's a look at Monarch Casino &amp; Resort's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.12</td>
<td>1.37</td>
<td>1.11</td>
<td>0.96</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.36</td>
<td>1.47</td>
<td>1.19</td>
<td>0.93</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>8.0%</td>
<td>7.000000000000001%</td>
<td>11.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745258513_0.png" alt="eps graph" /></p>
<h3>Tracking Monarch Casino &amp; Resort's Stock Performance</h3>
<p>Shares of Monarch Casino &amp; Resort were trading at $75.63 as of April 18. Over the last 52-week period, shares are up 6.75%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Insights Shared by Analysts on Monarch Casino &amp; Resort</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Monarch Casino &amp; Resort.</p>
<p>The consensus rating for Monarch Casino &amp; Resort is Neutral, based on 2 analyst ratings. With an average one-year price target of $86.0, there's a potential 13.71% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Rush Street Interactive, Accel Entertainment and Ballys, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Rush Street Interactive, with an average 1-year price target of $15.0, suggesting a potential 80.17% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Accel Entertainment, with an average 1-year price target of $16.0, suggesting a potential 78.84% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Ballys, with an average 1-year price target of $14.0, suggesting a potential 81.49% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for Rush Street Interactive, Accel Entertainment and Ballys, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monarch Casino &amp; Resort</td>
<td>Neutral</td>
<td>4.94%</td>
<td>$72.84M</td>
<td>0.82%</td>
</tr>
<tr>
<td>Rush Street Interactive</td>
<td>Outperform</td>
<td>31.11%</td>
<td>$92.55M</td>
<td>2.73%</td>
</tr>
<tr>
<td>Accel Entertainment</td>
<td>Outperform</td>
<td>6.88%</td>
<td>$96.65M</td>
<td>3.62%</td>
</tr>
<tr>
<td>Ballys</td>
<td>Neutral</td>
<td>-5.12%</td>
<td>$312.59M</td>
<td>-64.91%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Monarch Casino &amp; Resort ranks in the middle for Consensus rating. It is at the bottom for Revenue Growth. It is at the top for Gross Profit. It is at the bottom for Return on Equity.</p>
<h3>Delving into Monarch Casino &amp; Resort's Background</h3>
<p>Monarch Casino &amp; Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food &amp; Beverage and Hotel Operations.</p>
<h3>Key Indicators: Monarch Casino &amp; Resort's Financial Health</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Monarch Casino &amp; Resort showcased positive performance, achieving a revenue growth rate of <strong>4.94%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Monarch Casino &amp; Resort's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>3.13%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>0.82%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Monarch Casino &amp; Resort's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.62%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Monarch Casino &amp; Resort's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.03</strong>.</p>
<p><a href="https://www.benzinga.com/quote/MCRI/earnings"><strong>To track all earnings releases for Monarch Casino &amp; Resort visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MCRI

A Preview Of Monarch Casino & Resort's Earnings

<p>Peoples Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEBO#NASDAQ">PEBO</a>) will release its quarterly earnings report on Tuesday, 2025-04-22. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Peoples Bancorp to report an <strong>earnings per share</strong> (EPS) of $0.73.</p>
<p>Anticipation surrounds Peoples Bancorp's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company missed EPS by $0.00, which was followed by a 2.71% increase in the share price the next day.</p>
<p>Here's a look at Peoples Bancorp's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.76</td>
<td>0.82</td>
<td>0.84</td>
<td>0.80</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.76</td>
<td>0.89</td>
<td>0.82</td>
<td>0.84</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>1.0%</td>
<td>-1.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745258504_0.png" alt="eps graph" /></p>
<h3>Performance of Peoples Bancorp Shares</h3>
<p>Shares of Peoples Bancorp were trading at $27.85 as of April 18. Over the last 52-week period, shares are down 5.89%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/PEBO/earnings"><strong>To track all earnings releases for Peoples Bancorp visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


PEBO

Exploring Peoples Bancorp's Earnings Expectations

<p>Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) will release its quarterly earnings report on Tuesday, 2025-04-22. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Usana Health Sciences to report an <strong>earnings per share</strong> (EPS) of $0.74.</p>
<p>The market awaits Usana Health Sciences's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat EPS by $0.15, which was followed by a 3.91% increase in the share price the next day.</p>
<p>Here's a look at Usana Health Sciences's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.49</td>
<td>0.48</td>
<td>0.65</td>
<td>0.69</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.64</td>
<td>0.56</td>
<td>0.54</td>
<td>0.86</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>6.0%</td>
<td>-3.0%</td>
<td>10.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745258496_0.png" alt="eps graph" /></p>
<h3>Market Performance of Usana Health Sciences's Stock</h3>
<p>Shares of Usana Health Sciences were trading at $23.74 as of April 18. Over the last 52-week period, shares are down 47.55%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analyst Insights on Usana Health Sciences</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Usana Health Sciences.</p>
<p>Analysts have provided Usana Health Sciences with 1 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $36.0, suggesting a potential 51.64% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of  and Honest Co, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Honest Co, with an average 1-year price target of $7.0, suggesting a potential 70.51% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for  and Honest Co, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Usana Health Sciences</td>
<td>Neutral</td>
<td>-3.38%</td>
<td>$175.06M</td>
<td>0.84%</td>
</tr>
<tr>
<td>Honest Co</td>
<td>Neutral</td>
<td>10.61%</td>
<td>$38.77M</td>
<td>-0.53%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Usana Health Sciences ranks higher in revenue growth compared to its peers. However, it lags behind in gross profit margin. The company's return on equity is also stronger than its peers. Overall, Usana Health Sciences is positioned favorably among its peers based on these key metrics.</p>
<h3>Unveiling the Story Behind Usana Health Sciences</h3>
<p>Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.</p>
<h3>Usana Health Sciences's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Usana Health Sciences's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-3.38%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>2.1%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Usana Health Sciences's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>0.84%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Usana Health Sciences's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.63%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Usana Health Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.05</strong>.</p>
<p><a href="https://www.benzinga.com/quote/USNA/earnings"><strong>To track all earnings releases for Usana Health Sciences visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


USNA

Exploring Usana Health Sciences's Earnings Expectations

<p>Veritex Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBTX#NASDAQ">VBTX</a>) will release its quarterly earnings report on Tuesday, 2025-04-22. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Veritex Holdings to report an <strong>earnings per share</strong> (EPS) of $0.51.</p>
<p>Veritex Holdings bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>Last quarter the company missed EPS by $0.01, which was followed by a 0.71% drop in the share price the next day.</p>
<p>Here's a look at Veritex Holdings's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.55</td>
<td>0.55</td>
<td>0.53</td>
<td>0.56</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.54</td>
<td>0.59</td>
<td>0.52</td>
<td>0.53</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>2.0%</td>
<td>-2.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745258486_0.png" alt="eps graph" /></p>
<h3>Tracking Veritex Holdings's Stock Performance</h3>
<p>Shares of Veritex Holdings were trading at $21.79 as of April 18. Over the last 52-week period, shares are up 2.89%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/VBTX/earnings"><strong>To track all earnings releases for Veritex Holdings visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


VBTX

Insights Ahead: Veritex Holdings's Quarterly Earnings

<p>First Busey (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BUSE#NASDAQ">BUSE</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-22. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect First Busey to report an <strong>earnings per share</strong> (EPS) of $0.50.</p>
<p>The market awaits First Busey's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS beat by $0.02 in the last quarter, leading to a 1.88% increase in the share price on the following day.</p>
<p>Here's a look at First Busey's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.51</td>
<td>0.54</td>
<td>0.49</td>
<td>0.49</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.53</td>
<td>0.58</td>
<td>0.50</td>
<td>0.47</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>-1.0%</td>
<td>-3.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745258476_0.png" alt="eps graph" /></p>
<h3>Market Performance of First Busey's Stock</h3>
<p>Shares of First Busey were trading at $19.96 as of April 18. Over the last 52-week period, shares are down 15.37%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/BUSE/earnings"><strong>To track all earnings releases for First Busey visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BUSE

First Busey's Earnings Outlook

<p>In the last three months, 5 analysts have published ratings on Kimbell Royalty Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRP#NYSE">KRP</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $17.4, a high estimate of $23.00, and a low estimate of $14.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 9.61%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745258470_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The perception of Kimbell Royalty Partners by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<p>&#x7C;      Analyst       &#x7C;    Analyst Firm    &#x7C; Action Taken  &#x7C;    Rating     &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C;<br />
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C;<br />
&#x7C;Tim Rezvan          &#x7C;Keybanc             &#x7C;Lowers         &#x7C;Overweight     &#x7C;              $18.00&#x7C;$20.00              &#x7C;<br />
&#x7C;William Janela      &#x7C;Mizuho              &#x7C;Announces      &#x7C;Neutral        &#x7C;              $16.00&#x7C;-                   &#x7C;<br />
&#x7C;Neal Dingmann       &#x7C;Truist Securities   &#x7C;Lowers         &#x7C;Hold           &#x7C;              $16.00&#x7C;$22.00              &#x7C;<br />
&#x7C;Noah Hungness       &#x7C;B of A Securities   &#x7C;Lowers         &#x7C;Underperform   &#x7C;              $14.00&#x7C;$16.00              &#x7C;<br />
&#x7C;John Freeman        &#x7C;Raymond James       &#x7C;Raises         &#x7C;Strong Buy     &#x7C;              $23.00&#x7C;$19.00              &#x7C;</p>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Kimbell Royalty Partners. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Kimbell Royalty Partners compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Kimbell Royalty Partners's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Kimbell Royalty Partners's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/KRP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Kimbell Royalty Partners analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Kimbell Royalty Partners</h2>
<p>Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.</p>
<h3>Kimbell Royalty Partners: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Kimbell Royalty Partners's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately <strong>-16.16%</strong> in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-53.33%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-4.64%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Kimbell Royalty Partners's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-3.24%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.31</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing Kimbell Royalty Partners: Insights From 5 Financial Analysts

<p>Brandywine Realty Tr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDN#NYSE">BDN</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-04-22. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Brandywine Realty Tr will report an <strong>earnings per share</strong> (EPS) of $0.16.</p>
<p>Anticipation surrounds Brandywine Realty Tr's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $0.07, leading to a 5.04% drop in the share price on the subsequent day.</p>
<p>Here's a look at Brandywine Realty Tr's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.24</td>
<td>0.24</td>
<td>0.23</td>
<td>0.24</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.17</td>
<td>0.23</td>
<td>0.22</td>
<td>0.24</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>-14.000000000000002%</td>
<td>-4.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745258464_0.png" alt="eps graph" /></p>
<h3>Brandywine Realty Tr Share Price Analysis</h3>
<p>Shares of Brandywine Realty Tr were trading at $3.78 as of April 18. Over the last 52-week period, shares are down 18.89%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analyst Views on Brandywine Realty Tr</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Brandywine Realty Tr.</p>
<p>With 1 analyst ratings, Brandywine Realty Tr has a consensus rating of Neutral. The average one-year price target is $5.0, indicating a potential 32.28% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Piedmont Office Realty, Peakstone Realty Tr and Net Lease Office, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Piedmont Office Realty, with an average 1-year price target of $9.5, suggesting a potential 151.32% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Peakstone Realty Tr, with an average 1-year price target of $15.0, suggesting a potential 296.83% upside.</li>
<li>Analysts currently favor an Buy trajectory for Net Lease Office, with an average 1-year price target of $46.0, suggesting a potential 1116.93% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Piedmont Office Realty, Peakstone Realty Tr and Net Lease Office, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandywine Realty Tr</td>
<td>Neutral</td>
<td>-6.35%</td>
<td>$74.58M</td>
<td>-4.19%</td>
</tr>
<tr>
<td>Piedmont Office Realty</td>
<td>Buy</td>
<td>-1.44%</td>
<td>$84.63M</td>
<td>-1.86%</td>
</tr>
<tr>
<td>Peakstone Realty Tr</td>
<td>Neutral</td>
<td>-8.13%</td>
<td>$47.44M</td>
<td>1.19%</td>
</tr>
<tr>
<td>Net Lease Office</td>
<td>Buy</td>
<td>-40.23%</td>
<td>$16.68M</td>
<td>-5.95%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Brandywine Realty Tr ranks at the bottom for Revenue Growth and Gross Profit among its peers. It is in the middle for Return on Equity.</p>
<h3>Get to Know Brandywine Realty Tr Better</h3>
<p>Brandywine Realty Trust engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. The company owned and managed properties within five segments. The Philadelphia CBD segment includes properties located in the City of Philadelphia in Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Metropolitan Washington, D.C. segment includes properties in Northern Virginia, Washington, D.C. and Southern Maryland. The Other segment includes properties in Camden County, New Jersey and New Castle County, Delaware.</p>
<h3>Understanding the Numbers: Brandywine Realty Tr's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Brandywine Realty Tr's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-6.35%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Brandywine Realty Tr's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-36.73%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-4.19%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Brandywine Realty Tr's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-1.26%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Brandywine Realty Tr's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>2.15</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<p><a href="https://www.benzinga.com/quote/BDN/earnings"><strong>To track all earnings releases for Brandywine Realty Tr visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights into Brandywine Realty Tr's Upcoming Earnings

<p>Ratings for Paylocity Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NASDAQ">PCTY</a>) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Paylocity Holding and provided 12-month price targets. The average target is $238.93, accompanied by a high estimate of $270.00 and a low estimate of $190.00. Marking an increase of 5.92%, the current average surpasses the previous average price target of $225.57. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745258462_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Paylocity Holding by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<p>&#x7C;      Analyst       &#x7C;      Analyst Firm      &#x7C; Action Taken  &#x7C;     Rating      &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C;<br />
&#x7C;--------------------&#x7C;------------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C;<br />
&#x7C;Raimo Lenschow      &#x7C;Barclays                &#x7C;Lowers         &#x7C;Equal-Weight     &#x7C;             $204.00&#x7C;$231.00             &#x7C;<br />
&#x7C; Allan Verkhovski   &#x7C;Scotiabank              &#x7C;Announces      &#x7C;Sector Perform   &#x7C;             $190.00&#x7C;-                   &#x7C;<br />
&#x7C;Siti Panigrahi      &#x7C;Mizuho                  &#x7C;Lowers         &#x7C;Outperform       &#x7C;             $220.00&#x7C;$245.00             &#x7C;<br />
&#x7C;Patrick Walravens   &#x7C;Citizens Capital Markets&#x7C;Maintains      &#x7C;Market Outperform&#x7C;             $270.00&#x7C;$270.00             &#x7C;<br />
&#x7C;Raimo Lenschow      &#x7C;Barclays                &#x7C;Raises         &#x7C;Equal-Weight     &#x7C;             $231.00&#x7C;$214.00             &#x7C;<br />
&#x7C;Samad Samana        &#x7C;Jefferies               &#x7C;Raises         &#x7C;Buy              &#x7C;             $255.00&#x7C;$240.00             &#x7C;<br />
&#x7C;Patrick Walravens   &#x7C;JMP Securities          &#x7C;Raises         &#x7C;Market Outperform&#x7C;             $270.00&#x7C;$250.00             &#x7C;<br />
&#x7C;Brian Peterson      &#x7C;Raymond James           &#x7C;Raises         &#x7C;Outperform       &#x7C;             $265.00&#x7C;$215.00             &#x7C;<br />
&#x7C;Brad Reback         &#x7C;Stifel                  &#x7C;Raises         &#x7C;Buy              &#x7C;             $250.00&#x7C;$220.00             &#x7C;<br />
&#x7C;Kevin Mcveigh       &#x7C;UBS                     &#x7C;Raises         &#x7C;Neutral          &#x7C;             $220.00&#x7C;$211.00             &#x7C;<br />
&#x7C;Jason Celino        &#x7C;Keybanc                 &#x7C;Raises         &#x7C;Overweight       &#x7C;             $250.00&#x7C;$220.00             &#x7C;<br />
&#x7C;Scott Berg          &#x7C;Needham                 &#x7C;Raises         &#x7C;Buy              &#x7C;             $250.00&#x7C;$220.00             &#x7C;<br />
&#x7C;Arvind Ramnani      &#x7C;Piper Sandler           &#x7C;Raises         &#x7C;Overweight       &#x7C;             $254.00&#x7C;$212.00             &#x7C;<br />
&#x7C;Jason Celino        &#x7C;Keybanc                 &#x7C;Raises         &#x7C;Overweight       &#x7C;             $220.00&#x7C;$210.00             &#x7C;<br />
&#x7C;Siti Panigrahi      &#x7C;Mizuho                  &#x7C;Raises         &#x7C;Outperform       &#x7C;             $235.00&#x7C;$200.00             &#x7C;</p>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Paylocity Holding. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Paylocity Holding compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Paylocity Holding's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Paylocity Holding's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PCTY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Paylocity Holding analyst ratings.</strong></a></p>
<h2>All You Need to Know About Paylocity Holding</h2>
<p>Paylocity is a provider of payroll and human capital management solutions servicing small- to midsize clients in the United States. The company was founded in 1997 and targets businesses with 10-5,000 employees and services about 39,000 clients as of fiscal 2024. Alongside core payroll services, Paylocity offers HCM solutions such as time and attendance and recruiting software as well as workplace collaboration and communication tools.</p>
<h3>Financial Insights: Paylocity Holding</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Paylocity Holding's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>15.51%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Paylocity Holding's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>9.94%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Paylocity Holding's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>3.29%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.8%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Paylocity Holding's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.33</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PCTY

Deep Dive Into Paylocity Holding Stock: Analyst Perspectives (15 Ratings)

<p>Across the recent three months, 7 analysts have shared their insights on Synovus Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $53.86, a high estimate of $60.00, and a low estimate of $46.00. Experiencing a 11.91% decline, the current average is now lower than the previous average price target of $61.14. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745258453_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Synovus Financial. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<p>&#x7C;      Analyst       &#x7C;    Analyst Firm    &#x7C; Action Taken  &#x7C;    Rating     &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C;<br />
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C;<br />
&#x7C;Gary Tenner         &#x7C;DA Davidson         &#x7C;Lowers         &#x7C;Buy            &#x7C;              $60.00&#x7C;$65.00              &#x7C;<br />
&#x7C;Anthony Elian       &#x7C;JP Morgan           &#x7C;Lowers         &#x7C;Overweight     &#x7C;              $50.00&#x7C;$54.00              &#x7C;<br />
&#x7C;Karl Shepard        &#x7C;RBC Capital         &#x7C;Lowers         &#x7C;Outperform     &#x7C;              $52.00&#x7C;$64.00              &#x7C;<br />
&#x7C;Russell Gunther     &#x7C;Stephens &amp; Co.      &#x7C;Lowers         &#x7C;Equal-Weight   &#x7C;              $46.00&#x7C;$52.00              &#x7C;<br />
&#x7C;Timur Braziler      &#x7C;Wells Fargo         &#x7C;Lowers         &#x7C;Equal-Weight   &#x7C;              $50.00&#x7C;$60.00              &#x7C;<br />
&#x7C;Jared Shaw          &#x7C;Barclays            &#x7C;Lowers         &#x7C;Overweight     &#x7C;              $60.00&#x7C;$66.00              &#x7C;<br />
&#x7C;Manan Gosalia       &#x7C;Morgan Stanley      &#x7C;Lowers         &#x7C;Equal-Weight   &#x7C;              $59.00&#x7C;$67.00              &#x7C;</p>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Synovus Financial. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Synovus Financial compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Synovus Financial's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Synovus Financial's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SNV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Synovus Financial analyst ratings.</strong></a></p>
<h2>Discovering Synovus Financial: A Closer Look</h2>
<p>Synovus Financial Corp provides commercial and consumer banking in addition to a full suite of specialized products &amp; services such as private banking, treasury management, wealth management, mortgage services, premium finance, asset-based lending, structured lending, capital markets, &amp; international banking to clients through the wholly-owned subsidiary bank, Synovus Bank, and other offices in Alabama, Florida, Georgia, South Carolina, and Tennessee. It has four segments Wholesale Banking, Community Banking, Consumer Banking, and Financial Management Services, out of which the majority is from the Wholesale banking segment.</p>
<h3>Key Indicators: Synovus Financial's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Synovus Financial's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately <strong>-1.68%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Synovus Financial's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>32.18%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>3.84%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Synovus Financial's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.3%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Synovus Financial's debt-to-equity ratio surpasses industry norms, standing at <strong>0.43</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 7 Analyst Projections For Synovus Financial

<p><strong>Trustmark</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMK#NASDAQ">TRMK</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-22. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Trustmark will report an <strong>earnings per share</strong> (EPS) of $0.82. </p>
<p>The market awaits Trustmark's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company beat EPS by $0.09, leading to a 2.35% increase in the share price the following trading session.</p>
<p>Here's a look at Trustmark's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.83</td>
<td>0.82</td>
<td>0.62</td>
<td>0.61</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.92</td>
<td>0.84</td>
<td>0.66</td>
<td>0.68</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>-0.0%</td>
<td>-2.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745258449_0.png" alt="eps graph" /></p>
<h3>Market Performance of Trustmark's Stock</h3>
<p>Shares of Trustmark were trading at $32.75 as of April 18. Over the last 52-week period, shares are up 17.79%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/TRMK/earnings"><strong>To track all earnings releases for Trustmark visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


TRMK

Earnings Preview For Trustmark

<p>Looking into the current session, <strong>Sezzle Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>)</strong> shares are trading at $44.23, after a <strong>1.27%</strong> drop. Over the past month, the stock fell by <strong>8.99%</strong>, but over the past year, it actually increased by <strong>308.18%</strong>. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1745258445_0.png" alt="Past Year Chart" /></p>

<h3>Evaluating Sezzle P/E in Comparison to Its Peers</h3>
<p>The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. </p>
<p>Sezzle has a lower P/E than the aggregate P/E of <strong>62.23</strong> of the Financial Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1745258445_1.png" alt="Guage" /></p>

<p>In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions. </p>


Intraday Update

Markets

SEZL

P/E Ratio Insights for Sezzle

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>IBM</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with IBM, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 17 uncommon options trades for IBM.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 47% bullish and 41%, bearish.</p>
<p>Out of all of the special options we uncovered, 10 are puts, for a total amount of $685,260, and 7 are calls, for a total amount of $359,960.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $155.0 and $265.0 for IBM, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for IBM's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across IBM's significant trades, within a strike price range of $155.0 to $265.0, over the past month.</p>
<h3>IBM Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745258446_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>IBM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/25/25</td>
<td>$22.8</td>
<td>$22.8</td>
<td>$22.8</td>
<td>$255.00</td>
<td>$182.4K</td>
<td align="right">88</td>
<td align="right">176</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/25/25</td>
<td>$6.65</td>
<td>$6.25</td>
<td>$6.5</td>
<td>$245.00</td>
<td>$152.2K</td>
<td align="right">579</td>
<td align="right">234</td>
</tr>
<tr>
<td>IBM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/25/25</td>
<td>$19.3</td>
<td>$17.95</td>
<td>$18.49</td>
<td>$255.00</td>
<td>$147.6K</td>
<td align="right">88</td>
<td align="right">80</td>
</tr>
<tr>
<td>IBM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$7.45</td>
<td>$7.4</td>
<td>$7.4</td>
<td>$210.00</td>
<td>$72.5K</td>
<td align="right">680</td>
<td align="right">102</td>
</tr>
<tr>
<td>IBM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/25/25</td>
<td>$7.05</td>
<td>$6.8</td>
<td>$6.96</td>
<td>$230.00</td>
<td>$58.4K</td>
<td align="right">490</td>
<td align="right">438</td>
</tr>
</tbody>
</table>
</p>
<h3>About IBM</h3>
<p>IBM looks to be a part of every aspect of an enterprise's IT needs. The company primarily sells software, IT services, consulting, and hardware. IBM operates in 175 countries and employs approximately 300,000 people. The company has a robust roster of business partners to service its clients, which include 95% of all Fortune 500 companies. Primary products include its mainframes, Red Hat software, transaction processing software, and IT consulting.</p>
<p>In light of the recent options history for IBM, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is IBM Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 2,151,045, the IBM's price is down by -2.25%, now at $233.44. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 2 days.</li>
</ul>
<h3>What The Experts Say On IBM</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $270.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Jefferies continues to hold a Hold rating for IBM, targeting a price of $265.<br />
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $276. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for IBM with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

IBM Unusual Options Activity

<p>Across the recent three months, 5 analysts have shared their insights on DTE Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTE#NYSE">DTE</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $139.0, a high estimate of $147.00, and a low estimate of $135.00. This current average reflects an increase of 4.2% from the previous average price target of $133.40. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745258443_0_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A comprehensive examination of how financial experts perceive DTE Energy is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<p>&#x7C;      Analyst       &#x7C;    Analyst Firm    &#x7C; Action Taken  &#x7C;    Rating     &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C;<br />
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C;<br />
&#x7C;James Thalacker     &#x7C;BMO Capital         &#x7C;Raises         &#x7C;Market Perform &#x7C;             $142.00&#x7C;$135.00             &#x7C;<br />
&#x7C;Shahriar Pourreza   &#x7C;Guggenheim          &#x7C;Raises         &#x7C;Buy            &#x7C;             $147.00&#x7C;$139.00             &#x7C;<br />
&#x7C;David Arcaro        &#x7C;Morgan Stanley      &#x7C;Raises         &#x7C;Overweight     &#x7C;             $136.00&#x7C;$131.00             &#x7C;<br />
&#x7C;Nicholas Campanella &#x7C;Barclays            &#x7C;Lowers         &#x7C;Equal-Weight   &#x7C;             $135.00&#x7C;$137.00             &#x7C;<br />
&#x7C;James Thalacker     &#x7C;BMO Capital         &#x7C;Raises         &#x7C;Market Perform &#x7C;             $135.00&#x7C;$125.00             &#x7C;</p>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to DTE Energy. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DTE Energy compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of DTE Energy's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of DTE Energy's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DTE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on DTE Energy analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind DTE Energy</h2>
<p>DTE Energy owns two regulated utilities in Michigan that contribute 90% of earnings. DTE Electric serves approximately 2.3 million customers in southeastern Michigan, including Detroit. DTE Gas serves 1.3 million customers throughout the state. In addition, DTE has nonutility businesses and investments including energy marketing and trading, renewable natural gas facilities, and on-site industrial energy projects.</p>
<h3>DTE Energy: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining DTE Energy's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>1.24%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Utilities sector.</p>
<p><strong>Net Margin:</strong> DTE Energy's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>8.5%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> DTE Energy's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.51%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> DTE Energy's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.59%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> DTE Energy's debt-to-equity ratio is below the industry average at <strong>1.99</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On DTE Energy Through 5 Analysts

Press Releases

MAIA Biotechnology to Present at Biotech Showcase 2025

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology Announces Private Placement of $2,715,000

MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million

MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

MAIA Biotechnology Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIO

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug

MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders

MAIA

Adicet Bio

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Avalo Therapeutics

Citius Oncology

Fortress Biotech

FibroBiologics

Forte Biosciences

Gain Therapeutics

ImmuCell

Immix Biopharma

Immuneering Corporation - Class A Common Stock

Immuneering

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

PepGen

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Quince Therapeutics

Repare Therapeutics

Skye Bioscience

Sutro Biopharma

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Noble Capital Markets

Screenshot 2024-09-10 at 8.49.39 PM

Biotech

General

REGN

MAIA Biotechnology&#39;s Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits

Screenshot 2024-06-06 at 5.43.20 PM

New Clinical Data Reveals MAIA Biotechnology&#39;s THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment

Screenshot 2024-05-21 at 5.35.44 PM

MAIA Biotechnology&#39;s Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market

Comments

MAIA Biotechnology

Notizie

Ultime notizie per MAIA Biotechnology (AMEX:MAIA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO